https://www.selleckchem.com/products/U0126.html
Neurofilament light chain is a promising biomarker of disease activity and treatment response in relapsing-remitting multiple sclerosis (MS). Its role in progressive MS is less clear. The aim of the study was to assess the relationship between plasma neurofilament light chain (pNfL) and disease activity as defined by the concept NEDA-3 (No Evident Disease Activity), and brain volumetry, in a cohort of patients with the progressive disease form (PMS). Levels of pNfL (SIMOA technology) were examined in 52 PMS patients and analysed in relati
Like
Comment
Share
